REVIVA PHARMACEUTICALS HOLDINGS INC. - COMMON STO
0.4539
02-September-25 10:51:54
15 minutes delayed
Stocks
+0.0039
+0.87%
Today's range
0.4411 - 0.4583
ISIN
N/A
Source
NASDAQ
-
Reviva to Participate in the UBS Global Healthcare Conference
31 Oct 2024 05:00:00 By Nasdaq GlobeNewswire
-
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
08 Oct 2024 05:00:00 By Nasdaq GlobeNewswire
-
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
02 Oct 2024 05:30:00 By Nasdaq GlobeNewswire
-
Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference
26 Sep 2024 05:30:00 By Nasdaq GlobeNewswire
-
09 Sep 2024 05:00:00 By Nasdaq GlobeNewswire
-
Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
04 Sep 2024 05:00:00 By Nasdaq GlobeNewswire
-
27 Aug 2024 05:00:00 By Nasdaq GlobeNewswire
-
21 Aug 2024 03:00:00 By Nasdaq GlobeNewswire
-
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights
14 Aug 2024 05:00:00 By Nasdaq GlobeNewswire
-
06 Aug 2024 05:00:00 By Nasdaq GlobeNewswire
-
09 Jul 2024 05:00:00 By Nasdaq GlobeNewswire
-
29 May 2024 13:45:48 By Nasdaq GlobeNewswire
-
Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
28 May 2024 05:00:00 By Nasdaq GlobeNewswire
-
Reviva to Participate in the BIO International Convention
21 May 2024 05:00:00 By Nasdaq GlobeNewswire
-
15 May 2024 05:00:00 By Nasdaq GlobeNewswire
-
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
14 May 2024 05:00:00 By Nasdaq GlobeNewswire
-
13 May 2024 05:00:00 By Nasdaq GlobeNewswire
-
09 May 2024 05:00:00 By Nasdaq GlobeNewswire
-
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
15 Apr 2024 05:30:00 By Nasdaq GlobeNewswire
-
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
15 Apr 2024 05:05:00 By Nasdaq GlobeNewswire